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Objectives: To identify variables patients use to determine the severity of their asthma,
the perceived severity (PS), using a fuzzy decision-making analysis (FDMA). To compare
these variables with those involved in the assessment of asthma severity according to the
global initiative for asthma (GINA) guidelines, the objective severity (OS).
Patients: Outpatients (51 men, 62 women), aged (m7SD) 42.9716.3 years with
(% patients) mild intermittent (6.2), mild persistent (15.9), moderate (65.5) and severe
(12.4) asthma.
Design: Cross sectional, observational study.
Methods: Both OS (rated by doctors) and PS (rated by patients) were rated as mild
intermittent, mild persistent, moderate, or severe. Variables involved in OS assessment,
variables self-assessed by patients (dyspnea, perceived treatment efﬁcacy, asthma-related
quality of life questionnaire [AQLQ]), patients’ sociodemographic characteristics, and
asthma characteristics, were evaluated with questionnaires. These variables were pooled,
and considered as potential variables patients might use to determine their PS. They were
tested against the PS measurement using FDMA. This identiﬁed variables patients actually
used to determine PS.
Results: On the day of consultation, 68.1% of patients classed their asthma as mild
intermittent or mild persistent, 23.9% as moderate persistent, and 8.0% as severe
persistent. There was a signiﬁcant discrepancy (po0.01) between PS and OS with a clear
patient tendency to underestimate asthma severity as compared to OS. Patients
determined PS level according to variables assessing their asthma perception, i.e., AQLQ
measures and dyspnea, but not variables involved in OS assessment, such as symptomPublished by Elsevier Ltd.
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A. Lurie et al.2146frequency or knowledge of their peak ﬂow rates. Duration of asthma and treatment
characteristics were also involved.
Conclusion: FDMA identiﬁed variables patients used to determine PS. It highlighted a
discrepancy between patients’ and doctors’ perceptions of asthma severity, suggesting
that assessment of asthma severity should consider both patients’ and doctors’
perceptions of the disease and includes an AQLQ measure.
& 2007 Published by Elsevier Ltd.Introduction
The global initiative for asthma (GINA) guidelines recognize
four distinct levels of asthma severity (objective severity
(OS)).1,2 OS is assessed by rating a combination of symptoms,
lung function tests, and medication use, and is the key to
successful management using stepped care pharmacother-
apy. Although OS has been thoroughly studied, little
research has investigated patients’ perception of asthma
severity (perceived severity (PS)).3–12 Variables which have
been identiﬁed to inﬂuence patients’ perception of their
asthma burden include symptom frequency, symptom
bother, activity limitation, acute exacerbation,13 numbers
of missed workdays, overall health status, and prescriptions
for inhaled corticosteroids and long acting bronchodila-
tors.14 The correlation between self-PS of asthma and
objective assessment of severity on the basis of GINA
criteria15 or on the National Asthma Education and Preven-
tion Program Expert Panel II Management Guidelines has
been shown to be consistently poor.14 Patients with asthma
tend to underestimate their asthma severity as compared
with asthma severity assessed by physicians.15 In an
epidemiological study, patients with mild asthma have been
shown to be less prone to report their asthma than patients
with moderate or severe asthma.16 It seems, therefore, that
patients and physicians use different variables to deﬁne
asthma severity.
To our knowledge, the variables patients take into
consideration when rating the severity of their own asthma
(i.e., how they make the decision to rate the severity of
their own asthma as, for example, mild or severe) are not
known. Several kinds of variables may be involved in a
decision-making process. For numerical variables (e.g., peak
expiratory ﬂow rates, PEFR), a decision may vary depending
on whether the value is above or below a speciﬁed limit (the
threshold). For example, patients with usually normal PEFR
may be instructed to increase their dose of inhaled
corticosteroids when their PEFR is p60%. In reality, a
decision may depend on a fuzzy threshold (it may be 65%
or even ‘‘about 60%’’) or on intuitive, non-explicit variables
(as in subjective judgments). Methods using fuzzy logic are
suited to managing these variables, when a precise
mathematical description of a process is not possible.17–19
Fuzzy logic has been used to help decision-making in several
medical specialities.19–22 The methods are derived from the
fuzzy set theory that was introduced in 1965 by Zadeh23 to
simulate the process of human reasoning.17,19 A fuzzy set is
an extension of a classical set when the boundaries of the
set cannot be clearly deﬁned (Scheme 1).
Inductive learning analysis is used extensively when
performing data analysis to describe and to analyze data,in order to help a decision-making process.19–22,24,25 It
enables us to highlight dependence between variables.
When coupled with fuzzy logic (i.e., fuzzy decision-making
analysis, FDMA), it can provide a good simulation of
‘‘human’’ decision-making processes.17,19,23 It is a means
to identify and rank variables used in an individual’s
decision-making process.26,27 It shows the most probable
relationship between the identiﬁed variables and the
decision: for a given individual, the values of these
identiﬁed variables enable the result of their decision to
be predicted.
First, we used an FDMA to explore and rank by order of
importance the variables patients took into account to
determine their PS level. Next, we compared these
variables with those involved in the assessment of asthma
severity according to the GINA guidelines.
Methods
Patients
Asthmatic patients attending routine follow-up appoint-
ments were sequentially recruited from two respiratory
outpatient clinics, at Cochin University Hospital, Paris, and
the Hertford British Hospital, Levallois-Perret, France. At
the time that the study took place, the French Health Care
System allowed a patient to consult a specialist directly
without having previously consulted a general practitioner.
Exclusion criteria were co-existing chronic disease (such as
psychiatric or rheumatologic disorders), pregnancy, or
having given birth less than 3 months prior to inclusion.
The study was approved by the Cochin University Hospital
Ethics Committee, and all patients gave written informed
consent.
Design and description of the study
This study was conducted in naturalistic conditions, during a
single outpatient consultation.
Outcome measures
Variables assessed by patients
Assessment of asthma severity according to patients—PS.
PS on the day of consultation and over the past 6 weeks were
self-assessed by the patient using a 4-point Likert scale
(mild intermittent, mild persistent, moderate persistent,
and severe persistent).
Assessment of dyspnea, perceived response to treatment
success, and asthma-related quality of life. Dyspnea was
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Scheme 1 Overlap of fuzzy sets. To illustrate the overlap of fuzzy sets, let us consider the set of patients that perceive their asthma
as moderate (the ‘‘Perceived moderate’’ set) and the set of patients that perceive their asthma as severe (the ‘‘Perceived severe’’
set). Patients perceive their asthma asmoderate or severe depending on whether a given variable (labeled here ‘‘Var’’) is above or
below a threshold value. As the perception is subjective, a unique threshold value that separates the values of Var into 2 subsets does
not exist: the frontier between the ‘‘Perceived moderate’’ set and the ‘‘Perceived severe’’ set is fuzzy. In the fuzzy set theory, to
better reﬂect real life decision-making processes, the limit between two sets is not considered as a single value but is associated
with an interval of values. For example, when Var isp30, patients unquestionably perceive their asthma as moderate and, when Var
is X50, patients unquestionably perceive their asthma as severe. However, when Var ranges from 30 to 50, patients may perceive
their asthma as more or less severe depending on the value of Var.
Patients’ perception of asthma severity 2147assessed on the day of consultation and over the past
6 weeks using a 100mm horizontal visual analog scale,
from ‘‘not at all breathless’’ to ‘‘extremely breathless’’.
Perceived response to treatment was measured using a
5-point Likert scale (1 ¼ not at all effective to 5 ¼ very
effective). Asthma-related quality of life was measured
using the validated French version of the Marks—asthma
quality of life questionnaire (AQLQ),28,29 a 20-item ques-
tionnaire with Likert scale responses. Sub-scores for breath-
lessness, mood disturbance, social disruption, and concern
for health, were calculated.
Variables assessed by doctors
Assessment of asthma severity according to the GINA
guidelines—OS. Doctors assessed OS by answering a ques-
tionnaire, while referring to the patients’ case report forms.
Overall asthma severity, diurnal symptom severity, noctur-
nal symptom severity, exacerbation severity, and respiratory
function severity, were rated as mild intermittent, mild
persistent, moderate persistent or severe persistent.1,2
Symptoms mentioned on the case report forms included
cough, wheezing, dyspnea, and chest tightness. Treatment
‘‘severity’’ was similarly categorized according to the level
of pharmacotherapy used.1,2
Respiratory function tests. Forced expiratory volume
(FEV1) was determined with a Dyn’R
s spirometer (Dyn’R,
Le Muret, France). PEFR was measured with a MiniWright
peak ﬂow meter (Airmeds, London, UK). PEFR and FEV1
were expressed as the percentage of the predicted value.
Data analysis
FDMA
Fuzzy logic was applied to an inductive learning analysis to
produce a testable model of the variables patients took into
account to determine their PS level. The FDMA process is
described in Appendix. As about 40% of patients with mild PSseemed to have difﬁculties in discriminating mild inter-
mittent PS from mild persistent PS, these two categories
were collapsed into one category (mild PS). Thus, PS was
divided into three classes: mild, moderate, and severe PS.
FDMA identiﬁed and ranked variables patients may use to
determine their PS level. The variable ranked ]1, the root of
the decision-making process, represents the variable that is
the most important to all patients in determining their PS
level. The higher the rank (2nd, 3rd, etc.), the less
important the variable is in the decision making process.
Variables ranked greater than ﬁve were not considered as
they are associated with a too small number of patients to
be considered as important. As the same variable can be
used in different ranks of the process, it may appear twice.
Statistical analysis
Categorical variables were compared by w2 tests; p values
less than 0.05 were considered signiﬁcant. Analyses were
carried out using GB-STAT software (Dynamic Microsystems,
Silver Spring, MD).
Results
Study population and asthma characteristics. One hundred
and twenty ﬁve patients with asthma were asked to
participate in the study. Because the study simply required
the patients to complete a questionnaire while attending a
routine consultation, participation rate was high. Twelve
patients approached refused to participate. Data was not
collected on non-participants. One hundred and thirteen
adult outpatients with asthma (51 men, 62 women) were
recruited, with an average age (7SD) of 42.9716.3 years
(Table 1). Most patients were well educated, with 42.5%
having had tertiary (university) education (Table 2). Severity
according to GINA guidelines was (% of the total number of
patients): mild intermittent (6.2), mild persistent (15.9),
moderate persistent (65.5) and severe persistent (12.4).
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Table 1 Characteristics of patients’ asthma.
Asthma history (mean7SD)
Duration of asthma (years) 16.8714.1
Tobacco consumption (pack-years) 5.172.9
Number of visits to the doctora 4.374.3
Number of days missed at worka 2.379.9
Respiratory function (mean7SD)
FEV1 (% predicted) 83.6718.7
PEFR (% predicted) 81.5719.6
Asthma treatment (% patients)
Inhaled corticosteroid 91.1
Inhaled long-acting beta-2 agonist 36.3
Long-acting theophylline 7.9
Inhaled anticholinergic 3.5
Inhaled anti-allergic 3.5
Inhaled short-acting beta-2 agonist as
required
75.2
FEV1: Forced expiratory volume in 1 s; PEFR: peak expiratory
ﬂow rate.
aDuring the last 12 months.
Table 2 Socioeconomic characteristics of patients.
Education (% of patients)
Primary education only 4.4
Secondary education 8.0
Secondary technical education 16.0
Baccalaureat (high school leaving certiﬁcate) 23.8
Technical college 5.3
University degree 42.5
Family situation (% patients)
Single (never married) 29.3
Married/cohabiting 56.6
Divorced 9.7
Widowed 4.4
Occupational proﬁle (% patients)
Full-time work 46.0
Part-time work 8.0
Work at home 6.2
Student 14.2
Retired 16.8
Unemployed 3.5
Partial disability 5.3
Table 3 Dyspnea, treatment efﬁcacy, and quality of
life measurements as perceived by patients.
Variables studied Results
Dyspneaa (mean7SD, mm)
On the day of the study 23.3724.7
During the previous 6 weeks 31.1725.1
Perception of treatment efﬁcacy (% of patients)
Not at all effective 1.8
A little bit effective 5.3
Moderately effective 12.4
Effective 38.0
Very effective 42.5
AQLQb (mean7SD)
Total 2.372.0
Breathlessness 2.972.4
Mood disturbance 2.272.2
Concerns for health 2.272.1
Social disruption 1.972.1
aDyspnea was assessed using a 100mm horizontal visual
analog scale. The higher the score, the more breathless the
patient feels.
bAQLQ: asthma quality of life questionnaire. Total score
and sub-scores for breathlessness, mood disturbance, con-
cerns for health, and social disruption were calculated. Total
and subscale scores range from 0 to 10 (higher scores
represent a greater impact of asthma on quality of life).
A. Lurie et al.2148PS. On the day of consultation, 68.1% of patients classed
their asthma as mild, 23.9% as moderate persistent, and
8.0% as severe persistent. Over the preceding 6 weeks,
65.2% of patients classed their asthma as mild, 24.8% as
moderate persistent, and 10.0% as severe persistent. PS on
the day of the study and during the previous 6 weeks were
not statistically different (p40.05). There was a signiﬁcant
discrepancy (po0.01) between PS on the day of consultation
and OS with a clear patients’ tendency to underestimate
their asthma severity as compared to OS.Dyspnea, treatment efﬁcacy, and quality of life measure-
ments as perceived by patients are reported in Table 3.
Variables found to be used by patients to determine PS
level. These are reported in Table 4. Variables assessing the
patients’ perceptions of asthma (e.g., quality of life
measures, and dyspnea) were the most important, occupy-
ing the ﬁrst four ranks and accounting for six of the 13
variables. Variables assessing some aspects of treatment
characteristics were involved and ranked 3rd, 4th, and 5th,
i.e., ‘‘Oral corticosteroid use during the last 12 months’’
(rank ]3), ‘Total number of puffs’ and ‘‘Number of puffs of
inhaled corticosteroids’’ (rank ]4), and ‘‘Long-acting theo-
phylline use’’ (rank ]5). The PS also depended on patients’
demographic characteristics and asthma characteristics
(i.e., duration of asthma). However, variables assessing
asthma severity according to GINA guidelines, such as
symptom frequency or patient knowledge of their PEFR,
were not considered by patients to inﬂuence their PS.
Cross-validation tests showed a mean rate of 7377%,
indicating an accuracy of 73% (a decision taken from this
model can be considered correct in about three out of four
cases) with a high robustness (7%).Discussion
Our study shows (i) that FDMA identiﬁed and ranked the
variables actually used by patients to determine the severity
of their asthma, (ii) that these variables were very different
from those used by doctors to assess asthma severity, and
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Table 4 Variables found to be used by patients to
determine their asthma severity level, in decreasing
order of importance.
Rank of
order
Variables
Rank ]1 AQLQ concern for healtha,b
Rank ]2 Duration of asthmab
Dyspnea on the day of the studyb
Rank ]3 AQLQ concern for healthb
Duration of asthmab
Short course of oral corticosteroids during the
last 12 months
Perceived severity during the previous 6 weeks
Rank ]4 Age
Total number of puffs taken daily
Inhaled corticosteroids (number of puffs)
AQLQ breathlessness
Dyspnea on the day of the studyb
Rank ]5 Long-acting theophylline use
aAQLQ concern for health was found to be the root of the
decision-making process, which represented the variable
which was important to all patients in determining their PS
level. The other ranks show the other variables patients
used, in decreasing order of importance.
bThe same variable can be used at different level of a
decision-making process, and can thus appear at different
ranks. AQLQ: asthma quality of life questionnaire. The
relevant sub dimension of the AQLQ is shown in brackets.
Patients’ perception of asthma severity 2149(iii) the importance of AQLQ measures for patients in
determining their PS level.
Up to now, studies have used FDMA to develop decision-
making models.19–22 To our knowledge, our study is the ﬁrst
to use an FDMA to explore a patient’s decision-making
process. FDMA identiﬁed key variables patients used to
assess their PS level. It was created without prior model
speciﬁcation, unlike systems created solely by experts using
selected variables,30 which may ignore variables that are
important to patients. FDMA and statistics are two com-
plementary methods but rather different. In statistics, the
aim is to tackle problems associated with laws of probability
that govern them. In FDMA, no such hypothesis is assumed
and the aim is to tackle problems even if they are not
governed by an underlying law of probability. In our study,
the decision-making process is related to very subjective
knowledge (perception by the patients). We believe that a
law of probability explaining such subjective relations does
not exist, or, if such an underlying law does exist, that no
assumption about its properties can be made. Testing our
model against a ranking derived from statistical tests has the
limitation that the statistical tests are not appropriate for
these data. Moreover, FDMA has shown the most probable
relationship between these variables and the level of PS,
whereas studies that have used conventional statistics as
correlations have only shown that given variables are
associated to PS.3–12
Patients in this study tended to underestimate their
asthma severity. This was also remarkably and consistently
reported in an international survey in 29 countries assessinginternational variations in the severity and management of
asthma.15 The discrepancy between patient assessed sever-
ity and the severity according to the GINA guidelines is
interesting but may not be surprising. Firstly, there is no
agreed ‘‘gold standard’’ for classifying asthma severity, and
the lack of consensus between guidelines leads to discre-
pancies in severity assessment.1,2,8,31–35 Secondly, the
variables considered to be important to patients are not
central to GINA guidelines assessment of severity: (i) We
found that the way in which asthma affected the patient’s
life (i.e., quality of life and symptom perception) was more
important in their judgment of severity than symptom
frequency. The importance of quality of life in severity
assessment has been conﬁrmed by previous studies.6,14,36,37
Moreover, quality of life is only weakly correlated with
asthma symptoms, and is weakly or not at all correlated
with lung function.6,37–41 In the validation process of a
health-related quality of life measure, the face and content
validations take into account the perception of patients and
doctors, respectively. The use of AQLQ measure may
therefore improve asthma severity assessment from the
patients’ point of view. On the other hand, Schatz et al.13
identiﬁed that symptom frequency inﬂuenced the patients’
perception of their asthma burden, independently of
variables such as symptom bother, activity limitation, and
acute exacerbation. (ii) The importance accorded to asthma
duration by our patients has also been found in children, in
whom asthma duration is associated with objective mea-
sures of severity.42 (iii) The guidelines give weight to the
worst individual variable, which emphasize the importance
of nocturnal symptoms.4,7,43 We conﬁrmed the study by
Osman et al.44 who found that these are less important to
patients than daytime symptoms such as breathlessness. (iv)
Measurements of lung function heavily inﬂuence GINA
guidelines assessed severity, and these are known to
correlate poorly with patient reported symptoms.5,41,45 This
was also conﬁrmed by our study, which found that lung
function measurements (patient knowledge of their PEFR)
did not inﬂuence patients’ estimates of their disease
severity.
We cannot rule out that some patients might have
confused severity and control of their asthma. However,
the FDMA identiﬁed variables (e.g., those related to asthma
treatment) that GINA guidelines recommend to be used to
assess asthma severity.1,2 Measures that would distinguish
the construct of severity from that of control remain to be
identiﬁed.13 In fact, measures of control and severity are
not independent as shown by Combescure et al.46: asthma
control depends on the severity level of the disease
(this study was performed in naturalistic conditions which
were similar to those of our study). This may be related, in
part, to the fact that assessment tools for severity and
control of asthma use similar variables, e.g., symptom and
exacerbation frequency, and lung function.47
The results that we have do not permit us to explore the
differences between patients’ and doctors’ views of
severity. Like Yawn et al.,14 we can only conclude that
variables used by doctors to assess asthma severity are not
appropriate to assess the patients’ perception of their
asthma severity. Doctors need to develop a tool to assess
severity from both the physicians’ and the patients’
perspectives, used along with objective lung function tests
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Our ﬁndings support the suggestion that the clinical
parameters of the GINA guidelines and variables such as
health-related quality of life represent distinct dimensions
in the measurement of asthma severity, both of which are
valuable in determining the severity of the disease.37,48
The patients were recruited sequentially from two public
hospitals without evident recruitment bias. However, the
education level of our population was high, and there was a
slight predominance of women. When compared to male
gender, female gender is associated with a higher FEV1, a
critical determinant of the severity assessed with GINA
guidelines.37,49 Thus, we might expect that our patients
would have less severe asthma when compared with the
‘‘general population of patients with asthma’’. At the time
that the study took place, the French Health Care system
allowed patients to consult a specialist directly for care of
their asthma and the distribution of adult asthma severity in
secondary care was not known. The effect of our population
on quality of life scores is difﬁcult to determine, as the
increased health-related quality of life scores associated
with higher educational level3 may have been negated by
the reduced health-related quality of life scores associated
with female gender.37,49
In conclusion, we report, using a FDMA, a discrepancy
between patients’ and doctors’ perceptions of asthma
severity. Future studies assessing asthma severity should
take into consideration both patients’ and doctors’ percep-
tions of asthma severity and should include an AQLQ
measure. We believe that FDMA might be also applied in
various other domains in order to assess patients’ decision-
making processing or behaviors.
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Appendix. The FDMA
How the FDMA was performed using the set of
patients studied
Each patient is characterized by their PS level and the set of
values of all variables studied. The values of the variable
‘‘PS’’ (i.e., the PS level) indicate the result of a decision
process made by each of the patients to determine the
severity level of their own asthma. PS is divided into three
levels, i.e., mild, moderate and severe. The set of values of
all the variables studied included those involved in OS
assessment, variables self-assessed by patients (dyspnea,
perceived treatment efﬁcacy, asthma-related quality of life
questionnaire [AQLQ]), patients’ socio-demographic char-
acteristics, and asthma characteristics. A given patient was
described by means of a value of each variable, and was
associated with a given level of PS. For example, for a given
patient, ‘‘AQLQ concern for health ¼ 2’’, ‘‘Duration ofAsthma ¼ 15 years’’, ‘‘Dyspnea ¼ 30mm’’, ‘‘Age ¼ 37
years’’, ‘‘Oral CS ¼ yes’’, etc., were associated with ‘‘mild
PS’’. These variables were pooled, and considered as
potential variables patients might use to determine their
PS. They were tested against the PS measurement using
FDMA. This identiﬁed and ranked variables patients actually
used to determine PS, without making a priori assumptions
about relationships between variables.How variables used by patients to determine their
PS level were identiﬁed and ranked
The analysis was performed by means of the so-called Top
Down Induction of Decision Tree algorithm.50 The reasons we
chose this approach among others are explained below. The
analysis process was performed, ﬁrst, by determining the
variable ranked ]1, the root of the decision-making process,
which represents the variable that is the most important to
all patients in determining their PS level. Then, variables of
higher ranks were identiﬁed.
Identiﬁcation and ranking of variables of higher ranks
were done by successive splits of the set into subsets
according to the predictive values of variables: The predictive value of variables is such that: ‘‘knowing
values of important (i.e., informative) variables leads to
the knowledge of the PS level’’. The Shannon entropy, a
measure from the information theory, was used to assess
these predictive values.51 The entropy measures the link
existing between variables and PS. It is composed of the
probabilities of PS levels related to variables used by
patients to determine their PS level. The lower the
Shannon entropy, the more predictable the decision. For
example, a Shannon entropy is zero when an outcome is
inescapable (probability ¼ 1). The splits allowed the identiﬁcation of variables taken
into account by patients to determine their PS level, as
their PS level is different depending on whether the
considered variable is below or above a given split value.
In the case of FDMA, these values are fuzzy in order to
simulate the process of human reasoning, and to mirror
the non-explicit nature of decision-making.17,19
The set of patients was split according to the values of
each variable into as many subsets as values for these
variables. For instance, if the variable ‘‘Short course of oral
corticosteroids during the last 12 months’’ was selected, it
led to two subsets: the subset of patients with ‘‘Short course
of oral corticosteroids during the last 12 months ¼ yes’’ and
the subset of patients with ‘‘Short course of oral corticos-
teroids during the last 12 months ¼ no’’. For each subset,
two exclusive situations could occur: (i) if all patients from
the subset (or at least a signiﬁcant majority of them) are of
the same PS level, the variable is then identiﬁed as used by
patients to determine the PS level, (ii) if not, the process of
splitting is repeated on this subset. To do this, the Shannon
entropy is calculated allowing identiﬁcation and ranking of
the variables according to their predictive value. The best
decision-making process uses the minimum amount of
variables needed by patients to determine their PS
ARTICLE IN PRESS
Patients’ perception of asthma severity 2151level.17,52,53 The splitting values for continuous variables
were determined by a similar process.53
Cross-validation
In statistics, an a priori hypothesis is made before perform-
ing an analysis. The ‘‘sample size’’ and ‘‘statistical power’’
depend on the work hypothesis. On the contrary, FDMA does
not depend on an a priori hypothesis on the way patients
determine the severity of their asthma. The greater the
number of patients, the better (i.e., the more robust) the
model developed by the FDMA.
The model we obtained was validated by means of cross-
validation. This evaluates the accuracy and the robustness of
the model.54 The accuracy of the model to correctly predict
PS was tested by a so-called four-fold cross-validation test.
The whole set of patients was divided into four distinct
subsets, S1, S2, S3 and S4. Three of these subsets were
merged to perform a FDMA. The PS level of each patient from
the remaining subset was compared to that predicted by the
FDMA performed with the three merged subsets. The
percentage of good PS prediction measures the accuracy of
the FDMA. The greater the accuracy, the more reliable the
identiﬁcation and ranking of the variables patients may use to
determine their PS level. We aimed to perform a FDMA with
accuracy greater than 60%. This process was conducted four
times. Thus, four accuracies were obtained: one from testing
S4 with the model generated from S1+S2+S3, one from testing
S3 with the model generated from S1+S2+S4, another from
testing S2 with the model generated from S1+S3+S4 and
ﬁnally, one from testing S1 with the model generated from
S2+S3+S4. The statistical mean of these four accuracies
was used to assess the accuracy of the FDMA performed
with the whole set of patients. The standard deviation (SD) of
this mean was used to assess the robustness of the model
(the lower the SD, the more robust the model). The more
robust the model, the more conﬁdent we could be with the
accuracy of the FDMA. Analyses were carried out using the
Salammboˆ software (LIP6, Paris, France).52
Several fuzzy models were considered for this study: Models that classify patients, e.g., the fuzzy neural
network model. Knowing values of all variables related to
a given patient enables the determination of their PS
level. The Neural network models (also called ‘‘black
boxes’’) do not offer a fully interpretable model. They
classify patients according to their PS level, but do not
identify nor rank variables. Such a model could not be
useful in our study. Models that identify groups of patients. These models
enable the identiﬁcation of groups of patients with
similar PS levels according to the values of variables.
J Fuzzy clustering based approaches. The way of
measuring such a similarity between patients is not
possible without knowing the predictive value (i.e.,
the informative power) of each variable and their
combination. As this was the aim of our study, we
could not use this model.
J Bottom-up based ‘‘ifythen’’ rule algorithms. These
models build rules by merging patients one by oneuntil no more merging is possible, thus forming the
groups of patients. However, in the literature, this
model is generally only empirically explained, which
makes the interpretation of the rule construction
difﬁcult. Consequently, it is more difﬁcult to explain
the resulting sets, and we decided that such a model
could not be used in our study.
J The top-down based ‘‘ifythen’’ rule algorithms. This
is the FDMA model we used, as described above. Its
main advantage is that the interpretation of this FDMA
does not require speciﬁc knowledge in computer
science. One only has to understand the signiﬁcance
of variables used by patients. The variables identiﬁed
are ranked according to their importance in the
decision-making process. It is this relative simplicity
that explains our choice of this FDMA. In addition, the
novelty of our study relies on the use of the FDMA that
simulates the process of human reasoning, mirroring
the non-explicit nature of decision-making. FDMA can
be applied in various other domains in order to assess
patients’ decision-making processing or behaviors.References
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